Identification and Management of Tardive Dyskinesia 2022

This presentation on the identification and management of tardive dyskinesia 2022 reviews the relative prevalence of TD in patients with schizophrenia, mood spectrum disorders, and anxiety disorders; and the effective use of VMAT2 inhibitors without discontinuing other essential psychiatric treatments such as antipsychotics and antidepressants.
Christoph U. Correll, MD
Robert O. Cotes, MD
Jonathan M. Meyer, MD
Format: Adobe Acrobat (.pdf)
File Size: 490 KB
Released: May 11, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from:
Neurocrine Biosciences, Inc.

Related Content

Downloadable slides from the gut microbiome presentation at the 9th Annual Mood Disorders Summit 2022 (CCO)

Sarkis Mazmanian, PhD Released: November 10, 2022

Downloadable slides from the major depressive disorder presentation at the 9th Annual Mood Disorders Summit 2022 (CCO)

Greg W. Mattingly, MD Released: November 10, 2022

Downloadable slides from the digital therapeutics presentation at the 9th Annual Mood Disorders Summit 2022 (CCO)

Joseph F. Goldberg, MD Nicholas Jacobson, PhD Released: November 9, 2022

Downloadable slides from the anhedonia presentation at the 9th Annual Mood Disorders Summit 2022 (CCO)

Vladimir Maletic, MD Released: November 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings